Javascript must be enabled to continue!
METTL3-mediated RanGAP1 promotes colorectal cancer progression through the MAPK pathway by recruiting YTHDF1
View through CrossRef
AbstractRan GTPase activating protein 1 (RanGAP1) has been implicated in various diseases, but its role in colorectal cancer (CRC) progression remains unclear. Using tumor tissues and public databases, we found that RanGAP1 was significantly upregulated in CRC tissues and was associated with poor prognosis of patients. N6-methyladenosine (m6A) was found to play an important role in higher expression of RanGAP1. MeRIP-seq, RIP-qPCR, Luciferase reporter assays and other related experiment elucidated the molecular mechanism underlying m6A modification of RanGAP1. Besides, cell function experiments and xenograft tumor models corroborated the function of RanGAP1 in CRC progression. By RNA-seq and related analysis, RanGAP1 was verified to influent CRC progression via the Mitogen-Activated Protein Kinase (MAPK) signaling pathway. Therefore, N6-methyladenosine modification of RanGAP1 by METTL3/YTHDF1 plays a role in CRC progression through the MAPK pathway and could be a potential biomarker and therapeutic target for CRC.
Springer Science and Business Media LLC
Title: METTL3-mediated RanGAP1 promotes colorectal cancer progression through the MAPK pathway by recruiting YTHDF1
Description:
AbstractRan GTPase activating protein 1 (RanGAP1) has been implicated in various diseases, but its role in colorectal cancer (CRC) progression remains unclear.
Using tumor tissues and public databases, we found that RanGAP1 was significantly upregulated in CRC tissues and was associated with poor prognosis of patients.
N6-methyladenosine (m6A) was found to play an important role in higher expression of RanGAP1.
MeRIP-seq, RIP-qPCR, Luciferase reporter assays and other related experiment elucidated the molecular mechanism underlying m6A modification of RanGAP1.
Besides, cell function experiments and xenograft tumor models corroborated the function of RanGAP1 in CRC progression.
By RNA-seq and related analysis, RanGAP1 was verified to influent CRC progression via the Mitogen-Activated Protein Kinase (MAPK) signaling pathway.
Therefore, N6-methyladenosine modification of RanGAP1 by METTL3/YTHDF1 plays a role in CRC progression through the MAPK pathway and could be a potential biomarker and therapeutic target for CRC.
Related Results
Abstract 5961: The roles of METTL3 in colorectal cancer
Abstract 5961: The roles of METTL3 in colorectal cancer
Abstract
Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide, accounting for 10% of all cancer deaths. Metastatic disease occurs in h...
Abstract 920: COP1 E3 ligase regulates response to oncogenic MAPK pathway inhibition
Abstract 920: COP1 E3 ligase regulates response to oncogenic MAPK pathway inhibition
Abstract
Oncogenically activated RAS-MAPK pathway is the driver of several cancers including the majority of non-small cell lung adenocarcinomas (NSCLC). RAS-MAPK pa...
Structural dynamics of m6A formation in mRNA
Structural dynamics of m6A formation in mRNA
N6-Methyladenosin (m6A) ist die häufigste Modifikation in eukaryotischer mRNA. Der menschliche N6-Methyltransferasekomplex (MTC) methyliert cotranskriptionell das zentrale Adenin i...
Abstract 1737: METTL3-mediated m6A modification promotes tumor progression in upper tract urothelial carcinoma
Abstract 1737: METTL3-mediated m6A modification promotes tumor progression in upper tract urothelial carcinoma
Abstract
Upper tract urothelial carcinoma (UTUC), comprising 5% of urothelial neoplasms, is a rare malignancy arising from the transitional epithelium of the renal p...
METTL3 shapes m6A epitranscriptomic landscape for successful human placentation
METTL3 shapes m6A epitranscriptomic landscape for successful human placentation
Abstract
Methyltransferase-like 3 (METTL3), the catalytic enzyme of methyltransferase complex for m6A methylation of RNA, is essential for mammal...
The m6A Methyltransferase METTL3 Promotes Cisplatin Resistance and Invasion in Testicular Seminoma via BCL2
The m6A Methyltransferase METTL3 Promotes Cisplatin Resistance and Invasion in Testicular Seminoma via BCL2
Abstract
Background: Methyltransferase-like 3 (METTL3) involves in promoting tumor progression through tumor-related genes N6-methyladenosine (m6A) modification. Our previo...
Identification of microRNA-Regulated Pathways through a Integration of Mcrorna-mRNA Microarray and Bioinformatics Analysis in CD34+ Cells of Myelodysplastic Syndromes
Identification of microRNA-Regulated Pathways through a Integration of Mcrorna-mRNA Microarray and Bioinformatics Analysis in CD34+ Cells of Myelodysplastic Syndromes
Abstract
Background
MicroRNAs (miRNAs) are considered to play a key role in the pathogenesis of myelodysplastic syndromes (MDS). However, the effect o...
METTL3-mediated activation of Sonic Hedgehog signaling promotes breast cancer progression
METTL3-mediated activation of Sonic Hedgehog signaling promotes breast cancer progression
IntroductionBreast cancer represents a heterogeneous group of tumors characterized by diverse molecular and clinical features, driven by both genetic alterations and epigenetic reg...

